[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368378-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368378-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","small-molecule-mitotic-inhibitors-as-anticancer-agents-discovery-classification-mechanisms-of-action-and-clinical-trials","Small-Molecule Mitotic Inhibitors as Anticancer Agents - Discovery, Classification, Mechanisms of Action, and Clinical Trials","","Despite decades of research, cancer remains a major global concern with substantial mortality in the U.S. alone. Many therapies have been developed with differing mechanisms and toxicities, including small-molecule mitotic inhibitors that block mitosis and halt cancer cell proliferation, ultimately inducing cell death. The work reviews and classifies these inhibitors by discovery route, key chemical features, and mechanisms. It covers microtubule-related protein targeting, Checkpoint Kinase 1 inhibition-driven DNA damage, and mitotic kinase suppression, linking each to anticancer activity and current or investigational clinical trials, and discusses mitotic-inhibitor antibody–drug conjugates as targeted cytotoxic payloads.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/small-molecule-mitotic-inhibitors-as-anticancer-agents-discovery-classification-mechanisms-of-action-and-clinical-trials/368378/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/small-molecule-mitotic-inhibitors-as-anticancer-agents-discovery-classification-mechanisms-of-action-and-clinical-trials/368378.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are small-molecule mitotic inhibitors, and how do they work against cancer cells?","Question",{"text":63,"@type":64},"They inhibit cancer cell mitosis or self-replication, impeding cell proliferation and leading to cell death. Their anticancer activity is tied to disrupting mitotic processes and associated molecular targets.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the paper classify small-molecule mitotic inhibitors?",{"text":68,"@type":64},"It discusses classification through discovery, underlying chemistry, and mechanisms of action. The review organizes inhibitors by targets such as microtubule-related proteins, Checkpoint Kinase 1–linked DNA damage, and mitotic kinase proteins.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical trial and future prospects are addressed for anti-mitotic agents?",{"text":72,"@type":64},"Clinical trials for anti-mitotic agents are reviewed to track research progress, gauge current understanding, and identify possible future prospects. The paper also notes ongoing investigational inhibitors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368378,1791079589,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Review  \nSmall-Molecule Mitotic Inhibitors as Anticancer Agents: Discovery, Classification, Mechanisms of Action, and Clinical Trials  \nYazmin Salinas 1, Subhash C. Chauhan 2,3 and Debasish Bandyopadhyay 1,4, *  \nAcademic Editor: Shailesh Singh  \nReceived: 27 December 2024  \nRevised: 22 March 2025  \nAccepted: 25 March 2025  \nPublished: 1 April 2025  \nCitation: Salinas, Y.; Chauhan, S.C.; Bandyopadhyay, D. Small-Molecule Mitotic Inhibitors as Anticancer Agents: Discovery, Classification, Mechanisms of Action, and Clinical Trials. Int. J. Mol. Sci. 2025, 26, 3279 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26073279  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 School of Integrative Biological and Chemical Sciences, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA; [yazmin.salinas02@utrgv.edu](yazmin.salinas02@utrgv.edu)  \n2 Division of Cancer Immunology and Microbiology, Medicine, and Oncology Integrated Service Unit, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA; [subhash.chauhan@utrgv.edu](subhash.chauhan@utrgv.edu)  \n[3](3 South Texas Center of Excellence in Cancer Research)[ South Texas Center of Excellence in Cancer Research](3 South Texas Center of Excellence in Cancer Research) ([ST-CECR](ST-CECR)), McAllen, TX 78504, USA  \n4 School of Earth, Environmental, and Marine Sciences (SEEMS), The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA  \n* Correspondence: [debasish.bandyopadhyay@utrgv.edu](debasish.bandyopadhyay@utrgv.edu)  \nAbstract: Despite decades of research, cancer continues to be a disease of great concern to millions of people around the world. It has been responsible for a total of 609,820 deaths in the U.S. alone in 2023 . Over the years, many drugs have been developed to remove or reduce the disease’s impact, all with varying mechanisms of action and side effects. One class of these drugs is small-molecule mitotic inhibitors. These drugs inhibit cancer cell mitosis or self-replication, impeding cell proliferation and eventually leading to cell death. In this paper, small-molecule mitotic inhibitors are discussed and classified through their discovery, underlying chemistry, and mechanism(s) of action. The binding/inhibition of microtubule-related proteins, DNA damage through the inhibition of Checkpoint Kinase 1 protein, and the inhibition of mitotic kinase proteins are discussed in terms of their anticancer activity to provide an overview of a variety of mitotic inhibitors currently commercially available or under investigation, including those in ongoing clinical trial. Clinical trials for anti-mitotic agents are discussed to track research progress, gauge current understanding, and identify possible future prospects. Additionally, antibody–drug conjugates that use mitotic inhibitors as cytotoxic payloads are discussed as possible ways of administering effective anticancer treatments with minimal toxicity.  \nKeywords: small-molecule inhibitors; antibody–drug conjugates; mitosis; kinase proteins; microtubule-associated proteins; mitotic proteins; clinical trials; anticancer agent; cytotoxic; taxanes  \n1. Introduction  \nThe American Cancer Society estimated 1,958,310 new cancer cases and 609,820 cancer deaths in the United States for the year 2023 . Additionally, it was found that incidence numbers for breast, prostate, and uterine corpus have been on the rise. Although these numbers appear daunting, it is important to note that the cancer death rate decreased by 1.5% between the years 2019 and 2020 . Compared to data from 1991, this indicatesan estima","cbCaijtW6gLrgnDn","https://ap.wps.com/l/cbCaijtW6gLrgnDn","pdf",5191017,36,"English","# Abstract\n# Keywords\n# Introduction\n## Cancer epidemiology and treatment need\n## Mitotic inhibitors and key drug properties\n## Cell cycle and mitosis as anticancer targets","[{\"question\":\"What are small-molecule mitotic inhibitors, and how do they work against cancer cells?\",\"answer\":\"They inhibit cancer cell mitosis or self-replication, impeding cell proliferation and leading to cell death. Their anticancer activity is tied to disrupting mitotic processes and associated molecular targets.\"},{\"question\":\"How does the paper classify small-molecule mitotic inhibitors?\",\"answer\":\"It discusses classification through discovery, underlying chemistry, and mechanisms of action. The review organizes inhibitors by targets such as microtubule-related proteins, Checkpoint Kinase 1–linked DNA damage, and mitotic kinase proteins.\"},{\"question\":\"What clinical trial and future prospects are addressed for anti-mitotic agents?\",\"answer\":\"Clinical trials for anti-mitotic agents are reviewed to track research progress, gauge current understanding, and identify possible future prospects. The paper also notes ongoing investigational inhibitors.\"}]","Small-Molecule Mitotic Inhibitors as Anticancer Agents - Discovery, Classification, Mechanisms of Action, and Clinical Trials | PDF",1790176606,91,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ea3316af8cf1e476eec86b79aa8b636.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5921d9f9a04a0054593ae62d2de5f2f7.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e19a88cb3fbf1a2abb502666a0c70bdf.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/245a12c69ad1dfd3aaf47b335c6685fa.webp",980,1385]